Live Breaking News & Updates on Human Factors Study

Stay updated with breaking news from Human factors study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Petros Pharmaceuticals (PTPI) Completes Study in Effort to Switch STENDRA to OTC Status

Petros Pharmaceuticals (PTPI) Completes Study in Effort to Switch STENDRA to OTC Status
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Petros Pharmaceuticals Inc , Petros Pharmaceuticals , Human Factors Study , Human Factor Studies , Self Selection , Petro President , Chief Commercial Officer ,

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jules Abraham , Endo Pharmaceuticals , Petros Pharmaceuticals Inc , Petros Pharmaceuticals , Securities Exchange , Auxilium Pharmaceuticals , Exchange Commission , Human Factor Study , Human Factors Study , Human Factor Studies , Self Selection , Petro President , Chief Commercial Officer , Drug Facts Label , Label Comprehension Studies , Self Selection Studies , Actual Use Trial , Additional Conditions , Nonprescription Use , Non Arteritic Ischemic Optic Neuropathy , Erectile Dysfunction Therapies , Prescribing Information , Securities Act , Securities Exchange Act , Nasdaq Stock Market , Financial Condition ,

Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023

Q1 2023 Consolidated Revenue Grew 7%, Supported by 9% Growth in EGRIFTA SV® Revenue and 5% Growth in Trogarzo® Revenue Revised Sudocetaxel Zendusortide Phase 1 Trial. | April 12, 2023 ....

United States , Christian Marsolais , John Leasure , Elif Mcdonald , Philippe Dubuc , Julie Schneiderman , International Accounting Standards Board , Scientific Advisory Committee On , Development Pathway , Communications Corporate Affairs , Scientific Advisory Committee , American Association For Cancer Research , Company Management Discussion , International Financial Reporting Standards , Theratechnologies Inc , Revenue Grew , Sudocetaxel Zendusortide , Guidance Range Confirmed Between , Commercial Portfolio , Term Loan Facility , Marathon Asset , Marathon Asset Management , Loan Facility , Each Marathon Warrant , Opportunistic Infections , Cancer Research ,

Open Letter to Shareholders from CEO Paul Levesque

FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidanceFY2023 revenue guidance range set between $90 million and $95 million, ending ....

United States , Elif Mcdonald , Julie Schneiderman , Taimed Biologics , International Financial Reporting Standards , Scientific Advisory Committee , Drug Administration , Theratechnologies Inc , Communications Corporate Affairs , Development Pathway , Advisory Committee , Protocol Amendment , Second Intravenous , Biologics License Application , Human Factors Study , Positive Cash Flow , Chief Executive , Forward Looking Statements , Looking Statements , Annual Information Form ,

Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , Elif Mcdonald , Julie Schneiderman , Christian Marsolais , Philippe Dubuc , Partnership Strategy , Taimed Biologics Inc , Pennsylvania Cancer Specialists Research Centre , Communications Corporate Affairs , Quebec Breast Cancer Foundation , Mary Crowley Cancer Research , European Union , Karmanos Cancer Institute , Theratechnologies Inc , International Accounting Standards Board , International Financial Reporting Standards , Company Investor Relations , University Of Texas Md Anderson Cancer Center , Drug Administration , Company Intravenous Iv Push , Company Management Discussion , Sales Growth , Year To Date Revenue Growth , Revenue Growth , Binding Commitment , Non Dilutive Term Loan ,